/

  • linkedin
  • Increase Font
  • Sharebar

    Interleukin genetics unveils new oral preventative care

    How ILUSTRA might fit into your practice and help you provide more personalized care.

    Interleukin Genetics, Inc., a life science company focused on the genetics of chronic inflammation, unveiled the ILUSTRA™ Inflammation Management Program. The program targets individuals at elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation.   

    Under supervision of a licensed dentist or physician, ILUSTRA is offered by employers and through select insurance carriers as an enhanced benefit that has potential to provide significant health and economic value by improving the management of chronic inflammation.

    ILUSTRA incorporates three components:

    1. A simple yet technologically advanced genetic risk test 
    2. Targeted education to healthcare professionals to individualize care plans
    3. An 18-month subscription to the ILUSTRA Engagement Platform, a digital program to support plan members and drive behavior change 

    The ILUSTRA brand reflects the expanded program positioning and replaces the PerioPredict® brand name.

    Read more: 10 questions on genetic testing, periodontal disease and the role of the dental professional 

    “We are extremely excited about the launch of ILUSTRA, which is the result of several months of careful market research and testing,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “Customers said they want a turnkey program that delivers real impact. Our comprehensive approach delivers on this need by improving patients’ lives through better management of inflammation and has the potential to significantly reduce costs for plan sponsors. The ILUSTRA program provides a promising product to drive sales, and reflects our passion to make genetic insights actionable.”

    “Inflammation is strongly implicated in the onset and progression of several chronic diseases such as diabetes and cardiovascular disease,” said Kenneth Kornman, DDS, PhD, President and Chief Scientific Officer. “Evidence supports the value of managing patients by integrating both medical and dental science, and we see ILUSTRA as advancing care for chronic diseases through precision Dental-Medical Integration.”

    Related article: 5 things to consider regarding the connection between stroke and inflammation

    About the ILUSTRA Inflammation Management Program

    The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation. The program utilizes a genetic test to identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation. Such individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. The program integrates educational outreach to the patient’s care team and provides reminders and content to patients to drive engagement. The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit www.ILUSTRA.com.

    Interleukin Genetics, Inc.
    Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and ...

    0 Comments

    Add Comment
    • No comments available